Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02524951 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer
A Phase 1 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02524951: Clinical Trial Phase 1 study, sponsored by Northwell Health.
NCT02524951 is a Phase 1 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02524951, a Phase 1 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase I, open-label, dose escalation study. MSI-1436 will be administered as a single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
Primary Outcome
Subjects will be enrolled according to a standard Phase I Fibonacci design to receive MSI-1436C. If a subject has a dose-limiting toxicity (DLT) at any time during the study, MSI-1436C will be held and either re-started or discontinued in that subject as per the Dose Adjustments and Toxicities Guidelines.
Interventions
- DRUG MSI-1436C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2016-04 |
| Est. Completion | 2018-05-14 |
| Phase | Phase 1 |
Why NCT02524951 stopped before completion
NCT02524951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which MSI-1436C is the first listed.
NCT02524951 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02524951 about?
NCT02524951 is a clinical study titled "Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer". This is a Phase I, open-label, dose escalation study. MSI-1436 will be administered as a single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
What is the current status of trial NCT02524951?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2016-04. Estimated completion is 2018-05-14.
What interventions are being tested in trial NCT02524951?
The interventions under investigation include: MSI-1436C (DRUG).
Who is sponsoring clinical trial NCT02524951?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02524951's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia